FTC's authority to regulate advertising under Section 5 of the FTC Act — prohibiting unfair or deceptive acts or practices — is the primary legal framework governing health claims in supplement and functional food advertising. FDA governs label claims. FTC governs advertising claims. In practice, the two agencies coordinate, and the same claim on a website or in social media that FDA reviews as a potential disease claim is also evaluated by FTC for substantiation.

FTC's substantiation standard requires that health benefit claims be supported by "competent and reliable scientific evidence" — meaning tests, analyses, research studies, or other evidence based on the expertise of professionals in the relevant area, conducted and evaluated in an objective manner by persons qualified to do so.

That standard has been interpreted through decades of enforcement actions, consent orders, and guidance documents. Here's what it means in practice.

The Two-RCT Benchmark for Efficacy Claims

FTC has repeatedly applied a benchmark in supplement enforcement that many brands find surprising: for efficacy claims — claims that a supplement produces a specific clinical outcome in humans — FTC generally expects support from at least two well-designed, double-blinded, placebo-controlled, randomized controlled trials (RCTs) with statistically significant results.

This benchmark emerged from FTC's enforcement actions in the weight loss, brain health, and immunity supplement categories over the past two decades. It's not a codified statutory requirement, but it represents FTC's operational standard in high-risk categories.

The implication: if your supplement claims to "increase testosterone levels," "improve cognitive function," or "boost metabolism," and you have one study — even a well-designed one with significant results — FTC may find that insufficient. If you have three studies with mixed results (two positive, one null), the body of evidence may not support the specific efficacy claim in your advertising.

What "Well-Designed" Means

Not all studies count equally. FTC evaluates the quality of the evidence, not just the quantity. The characteristics that define a "well-designed" study for substantiation purposes:

Double-blinded: Neither the participants nor the researchers administering the study know who is receiving the active treatment. Open-label studies, where both parties know the treatment assignment, are not well-controlled and carry significant placebo and confirmation bias risk.

Placebo-controlled: The study compares the active treatment to an inert placebo, not just to baseline. Before-and-after studies with no control group cannot establish that the observed change was caused by the treatment rather than the passage of time, regression to the mean, or confounding variables.

Randomized: Participants are randomly assigned to treatment and control groups. Non-randomized studies where participants choose their group introduce selection bias.

Statistically significant: The study results reach the conventional threshold for statistical significance (p < 0.05 in most research), indicating that the observed effect is unlikely to be due to chance. Trend-level results (p = 0.08) do not meet this standard for advertising substantiation.

Conducted in the relevant population: A study conducted in elderly adults with nutritional deficiencies doesn't substantiate a claim for healthy young adults. A study conducted in rats or cell cultures doesn't substantiate a human efficacy claim at all.

Using the relevant ingredient at the relevant dose in the product's actual formulation: A study of curcumin at 1,000mg/day with a specific phospholipid delivery system doesn't substantiate a claim for a product with 200mg of curcumin without the delivery system.

The Dose-Match Problem

One of the most common substantiation failures in supplement marketing: citing clinical research that used a dose of an ingredient that's different from what's in the product.

If a magnesium supplement claims to "support restful sleep" based on research showing benefit at 500mg/day of magnesium glycinate, and the product contains 100mg per serving, the research doesn't substantiate the claim for the product as formulated.

FTC has cited this issue in enforcement actions — noting that brands may cite legitimate clinical research but fail to verify that their product delivers the studied dose or form of the ingredient. A proprietary blend that contains an unknown amount of each ingredient is particularly vulnerable: if the brand can't establish that the product delivers a dose consistent with the research, the claim based on that research may not be substantiated.

Mechanistic Evidence and Animal Studies

Mechanistic evidence — studies showing how an ingredient interacts with biological pathways in cell cultures or animal models — and animal studies are generally not sufficient alone to substantiate human health benefit claims.

FTC acknowledges that mechanistic evidence can provide biological plausibility. But biological plausibility is not the same as demonstrated human efficacy. A mechanism by which an ingredient could theoretically increase nitric oxide production in smooth muscle doesn't substantiate the claim that the supplement "improves cardiovascular circulation" in humans.

This is a very common gap in supplement marketing: brands build their claim language on the research rationale for why their ingredient should work, rather than on human clinical evidence that it does work. The FTC standard asks for the latter.

Testimonials Are Not Substantiation

Consumer testimonials — "I lost 20 pounds using this supplement" — cannot substitute for competent and reliable scientific evidence. They can accompany substantiated claims as supporting endorsements. But testimonials alone do not establish that a product produces the claimed benefit.

FTC has specific rules about testimonials in supplement advertising:

Atypical results: If a testimonial presents results that are not typical — and extraordinary weight loss claims are almost always not typical — the disclosure must be clear and conspicuous and must state what typical results are. "Results not typical" in fine print doesn't meet this standard. The disclosure must be specific: "In a clinical study, participants lost an average of 3 pounds over 12 weeks" or equivalent.

Paid relationships: If the testimonial comes from a paid endorser or someone who received free product, that material connection must be disclosed — both the relationship and the fact that the testimonial reflects the individual's experience, not a typical outcome.

Expert endorsements: If a doctor, scientist, or other expert endorses the product, the expert must have relevant expertise and must base their endorsement on a reasonable evaluation of the scientific evidence — not just agreement to be paid to appear in advertising.

Substantiation Documentation

FTC expects brands to have substantiation in their possession before making a claim — not to develop it in response to an inquiry. The documentation requirement means:

• Maintaining the specific clinical studies, systematic reviews, and meta-analyses that support each material claim

• Documenting the connection between the research and the product (dose, form, population)

• Being able to produce the substantiation record if FTC issues a compulsory process request or a warning letter asking for documentation

A claim can be truthful and still be unsubstantiated. "Vitamin D supports immune function" is truthful — the FDA has recognized structure/function claims for vitamin D and immune function. But "our specific vitamin D product reduces the risk of getting sick by 40%" is an efficacy claim that requires specific human clinical evidence for the exact claim.

High-Risk Claim Categories

FTC applies its heaviest substantiation scrutiny to the categories with the most consumer harm potential and the most history of fraudulent marketing:

Weight loss and body composition: Any claim that a product causes or significantly contributes to weight loss, fat burning, or metabolic rate increase. The two-RCT benchmark is routinely applied. Claims about specific amounts of weight loss in specific time periods require direct clinical evidence for those specific outcomes.

Cognitive enhancement and brain health: Claims about memory, focus, attention, and cognitive decline prevention. FTC has pursued numerous enforcement actions in this category, particularly against products marketed for Alzheimer's disease prevention or cognitive decline.

Testosterone and men's health: Claims about testosterone levels, libido, and "male vitality" are heavily scrutinized. Many ingredients marketed for testosterone support have weak clinical evidence at best.

Immunity: Post-pandemic, immunity claims have received sustained FTC attention. Claims about "preventing illness," "protecting against viruses," or "reducing the risk of infection" require specific human clinical evidence and risk being characterized as disease claims by FDA.

Substantiation Is Built Before the Claim Is Made

FTC enforcement is reactive — it comes after a complaint, a survey, or a market sweep identifies a potentially unsubstantiated claim. By the time FTC investigates, the claim has usually been in market for months or years. Building substantiation before making the claim, and maintaining documentation of the research basis, is the operational standard that keeps brands on the right side of enforcement.

Truli's AI compliance platform flags claims that appear to lack the specificity or scientific grounding typical of well-substantiated supplement marketing — and the Claims Hub maintains a substantiation record for every claim, linked to the regulatory reference and research basis. Book a demo to see how Truli manages substantiation documentation across your claims portfolio.